Technology
AEBi
Breakthrough
Compounds
Defined Target
In the year 2000, Dr. Ilan Morad had an idea as to how to create what can be described as a functional Phage Display. With this idea he applied for the ITEK incubator in the Weizmann Science Park. Six years later, AEBi was able to prove that the novel technology, titled 'SoAP', really works.
Within the Phage Display family, and unlike other members of this family of technologies, AEBi's platform provides functional leads to very difficult targets (functional leads - agonist, antagonist, inhibitor, etc.), not merely those that best bind with the target.
- SoAP allows AEBi to develop drugs to many illnesses, among them cancer, and is expected to transform the drug discovery R&D phase by significantly reducing the attrition rate of new drug candidates.
-
This Breakthrough technology generates very specific lead compounds with greater functionality and improved pharmacological properties.
- Such lead Compounds will allow more effective drugs and fewer side effects. The need for such technology is acute and pressing for many reasons.
- The sole external requirement in the screening process is a Defined Target (usually an illness-related protein).
Link to our patented Drug Discovery Platform http://bit.ly/367Jtkk
Soap's Advantages over existing technologies are myriad:
Rapid isolation and identification of lead compounds.
Our solution will hit and activate or deactivate any protein-based target.
Isolation of lead compounds from vast libraries.
Dramatically expands the range of targets, to include even the most challenging ones.
Selection conditions can be alerted to isolate lead compounds with particular functional characteristics (agonist, antagonist, inhibitors, etc.).
Unparalleled high "signal to noise" ratio.
In-process library enrichment.
AEBi Platform features:
No limit on the number of rounds in the screening process.
Each round has both affinity and efficacy properties.
Hitting the hardest targets.
About Us
Biopharmaceutical
Therapeutic
Peptides
Combinatorial
Biology
AEBi was established in the year 2000, and has been managed since then based on the idea that the ability to manipulate and design peptides has vastly superior advantages to many, if not any, existing and trajectory technologies of drug development. This idea is valid today as well.
The basic idea is that we do not require a natural lead or a sequence (usually coming from the academia or other research) which are either not strong enough or not specific enough and difficult to manipulate in order to create a drug.
An artificial high complexity pool, representing a broad spectrum of possibilities, manipulated by our technology, will provide the best possible solution. Such a solution will not be hindered or blocked by natural interactions and will be very specific to the problem.
AEBi, a development-stage biopharmaceutical company engaged in discovery and development of therapeutic peptides, has developed a combinatorial biology screening platform technology (IP protected).
The major advantage is that it can be used not only to find binders to known targets, but to select the best functional molecules among them.
AEBi's platform is very flexible, exploiting combinatorial biology to discover new and better lead compounds to disease targets.
AEBi MANAGEMENT APPROACH
Positive Black Swans
- Focusing on the science & technology on the critical path to proof of concept - The Richard Feynman principle.
- Research & Development of a comprehensive fundamental idea - The Capecchi principle.
- Don't water down the solution in order to generate Investor\Pharma\Media traction - The Clayton Christensen principle.
- Transparent Management practices - Our principle.
- Private investors with a long term outlook, adhering in advance to the Company's goals and methods - The practical approach that worked for us.
- We do not engage in Financial wizardry - No Debt, No Bank Credit, No Loans.
Radiotherapy first used to treat cervical cancer
First link made between sun and skin cancer
Proof of a link between smoking and lung cancer first published
First chemotherapy drug, methotrexate, used to treat a rare tumor called choriocarcinoma
Discovery of the first human cancer virus
First drug for testicular cancer developed, now 95 per cent of men with it survive
The first ‘monoclonal antibody’ or targeted therapy approved by the Federal Drug Administration (later examples include Herceptin for breast cancer and Avastin for colorectal, lung and other cancers)
The first breast cancer genes BRAC1 and BRAC2 discovered
The cervical cancer vaccine immunization program begins in the UK
Trials show "flexi-scope" screening could prevent a third of bowel cancers
International Cancer Genome Consortium formed to map the genetic faults behind 50 types of cancer
Trial finds taking the drug anastrazole daily could halve the risk of breast cancer in high-risk older women
Scientists build nanoparticles that act as "Trojan Horse" vessels that ferry chemotherapy drugs directly to cancers. Breast cancer drugs are shown to shrink or eliminate tumours in 11 days
AEBi was incorporated in June 2000 at the ITEK Weizmann technology incubator, ISRAEL.
Finalized the basic technological platform development.
Library with a complexity of 1 Million peptides, based on 5 or 15 amino acids.
First external validation by other Pharma companies. Tests done independently - targeted protein inside the cell.
First peptides show affinity & efficacy on known and hard to hit targets.
Finalizing the development of the second version of the technological platform.
Libraries of 12 amino acids long cyclic peptides, with a complexity of 100M.
Perfecting the platform mechanics.
Collect results of our lead project of an anti-cancer peptide.
Additional peptides were isolated that show much higher efficacy.
Testing various cancer treating concepts.
Using the "Trojan Horse" approach. In vitro repeated tests show ability to hit and destroy cancer cells in a discriminative manner.
A comprehensive review of our work can be seen at the magazine Pharmafile (Pharmafocus.com) pages 16-19
Links to Patnets ;Links to Media about us
Clayton Christensen
"Rarely is the development of the absence of a product the problem in a company. Almost all companies are awash in ideas for new products. What they don't do - and they could but they choose not to - is to create new business models that are tailor-made to the characteristics of the new product. You come up with this great idea, and you can't do anything with it unless you get funded. To get funded, you have to, little by little, morph and shape and modify your business plan so that it fits the current business model. If it doesn't fit the business model, they don't perceive that it will be successful. So what comes out of the process is incremental innovation after me-too innovation. It's not that original idea wasn't innovative, but in order to get it funded, you have to change your strategy so that it ultimately conforms to your company, rather than to the problem or unmet need in the market."
Clayton Christensen coined the term and pioneered the study of modern "Disruptive Technology".
- AEBI Drug discovery patented platform
- AEBi MuTaTo patent request
- Dr Morad interview English
- Pharmafile article by AEBi
- Professor William Reville
- Nobel Laureate Levitt on MuTaTo
- The cutting edge cancer research
- Dr Eva Glazer
- Dr Nandi
- MyBiogate
- Dr. Thaïs Aliabadi
- Ami Magazine. - Regarding a complete cure
- WorldBI promo to Dr Morad Presentation Munich 2018
- Game Changing potential
- New Thought Model - Dr. Ray Schilling
- It might just be real - eaglegatecollege.edu
- futuretechpodcast.com - Interview Dr Morad
- If not Darwin, who?